Your browser doesn't support javascript.
loading
Low disease risk and penetrance in Leber hereditary optic neuropathy.
Watson, Eloise C; Davis, Ryan L; Ravishankar, Shyamsundar; Copty, Joseph; Kummerfeld, Sarah; Sue, Carolyn M.
  • Watson EC; Department of Neurogenetics, Kolling Institute, Faculty of Medicine and Health, University of Sydney and Northern Sydney Local Health District, Reserve Rd, St Leonards, NSW, Australia; Department of Neurology, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW, Austr
  • Davis RL; Department of Neurogenetics, Kolling Institute, Faculty of Medicine and Health, University of Sydney and Northern Sydney Local Health District, Reserve Rd, St Leonards, NSW, Australia.
  • Ravishankar S; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
  • Copty J; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
  • Kummerfeld S; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; St Vincents Clinical School, UNSW, Sydney, NSW, Australia.
  • Sue CM; Department of Neurogenetics, Kolling Institute, Faculty of Medicine and Health, University of Sydney and Northern Sydney Local Health District, Reserve Rd, St Leonards, NSW, Australia; Department of Neurology, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW, Austr
Am J Hum Genet ; 110(1): 166-169, 2023 01 05.
Article en En | MEDLINE | ID: mdl-36565700
ABSTRACT
The risk of Leber hereditary optic neuropathy (LHON) has largely been extrapolated from disease cohorts, which underestimate the population prevalence of pathogenic primary LHON variants as a result of incomplete disease penetrance. Understanding the true population prevalence of primary LHON variants, alongside the rate of clinical disease, provides a better understanding of disease risk and variant penetrance. We identified pathogenic primary LHON variants in whole-genome sequencing data of a well-characterized population-based control cohort and found that the prevalence is far greater than previously estimated, as it occurs in approximately 1 in 800 individuals. Accordingly, we were able to more accurately estimate population risk and disease penetrance in LHON variant carriers, validating our findings by using other large control datasets. These findings will inform accurate counseling in relation to the risk of vision loss in LHON variant carriers and disease manifestation in their family. This Matters Arising paper is in response to Lopez Sanchez et al. (2021), published in The American Journal of Human Genetics. See also the response by Mackey et al. (2022), published in this issue.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Atrofia Óptica Hereditaria de Leber Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Atrofia Óptica Hereditaria de Leber Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article